Tag Archives: NOVO

Positive Pants Part 1: Novo 2026 Capital Markets Day Highlights and Analysis

Novo hosted its 2026 Capital Markets Day and provided updates on the strategic direction of the company across key commercial and R&D activities (view slides). While The Street and media sentiment seemed to be unduly negative on Novo’s direction (as evidenced by the -8% drop in the stock price), it appears the ongoing strong Wegovy pill launch and impending cagrisema launch should position the company to meet its operational targets in the next 3-5 years. However, the company may be challenged in the longer term, particularly as semaglutide approaches broader LOE. Below, FENIX provides details and insights from the event in Part 1 of 2. Part 2 will cover the importance of manufacturing and commercial execution with reflections from our May 2025 Obesity Spotlight on Novo Nordisk.

This content is for Read Less members only.
Already a member? Log in here

Novo Initiates Zenagamtide CVOT in Obesity; Novo Enters Purchase Agreement for Three Obesity Programs with Kallyope; Health Canada Approves Sandoz Generic Sema

Three cardiometabolic-related news items have been observed: Novo initiated a Ph3 study evaluating zenagamtide for ASCVD (view EUClinicalTrials record); Novo has entered into an asset purchase agreement with Kallyope to acquire three novel obesity drug programs (view LinkedIn post); and Sandoz received Health Canada approval for its generic semaglutide (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Pfizer Initiates Ph3 Berobenatide OSA Study; Novo Ph3 Zenagamtide Study in Japan; Novo and Anthropic Partner for Drug and AI Development

Three cardiometabolic-related news items have been observed: Pfizer initiated the Ph3 QM berobenatide VESPER-OSA 1 study (view CT.gov record); Novo initiated the zenagamtide AMAZE 10 study in Japanese patients with obesity (view CT.gov record); and Novo and Anthropic entered into a collaboration to accelerate Novo’s drug development and AI-driven software development (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in India

A series of cardiometabolic-related news items has been observed from Ascendis Pharma, Novo, Dexcom, Arrowhead Pharmaceuticals, Elvinix, Lilly, MiniMed, and Tracky. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Rebranding; Corbus Topline Ph1b CB1 Data; New Foundayo DTC TV Ads; New Alveus Ph2 Obesity Study; Beta Bionics Patch Pump FDA Clearance; Senseonics Integrates with Beta Bionics’s iLet AID; September CHMP Agenda

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Corbus Pharmaceuticals, Lilly, Alveus Therapeutics, Beta Bionics, Senseonics, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

JPM 2026 Day 3: ZLDPF, ABBV, SANA, PODD; Jazz to Sell PRV; Novo Initiates Amycretin Ph3 Program; Madrigal Initiates New Ph2 Resmetirom MASH Study; Sandoz Confirms EC Approval of Ondibta

On the third day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Zealand, AbbVie, Sana Biotechnology, and Insulet. Separately, a series of CVRM-related news items has been observed. Below, FENIX provides highlights and insights for the respective news items, including speculation into who purchased Jazz’s PRV.

This content is for Read Less members only.
Already a member? Log in here

Madrigal Licenses MASH Assets from Pfizer; Wegovy Pill Available on Amazon; New BI MASH Asset; Alveus Launches as Clinical-Stage Biotech; Zealand Partners for AI Drug Discovery; Lilly Expands TuneLab

A series of cardiometabolic-related news items has been observed from Madrigal/Pfizer, Novo Nordisk, Boehringer Ingelheim, Alveus Therapeutics, Zealand Pharma, and Lilly. Below, FENIX provides highlights and insights into the respective news items, including speculation into BI’s new MASH asset MOA.

This content is for Read Less members only.
Already a member? Log in here

Arrowhead Ph1/2 RNAi-Based Obesity Results; MindRank Ph3 Oral GLP-1RA Program; Altimmune Receives Breakthrough Therapy Designation; Nimbus and Lilly Partner for Obesity; Roche and Structure Patent Agreement; Novo Debuts Report on America’s Obesity Epidemic

A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, MindRank, Altimmune, Nimbus Therapeutics/Lilly, Roche/Structure Therapeutics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here